Boston Immune Technologies & Therapeutics

0 followers

‌

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

Industries

Biotechnology, Therapeutics

Headquarters

Winchester, United States

Employees

1-10

Links

Org chart

Russell LaMontagne

CEO

Collapse

David Brooks

Chief Medical Officer

Bruce Weaver

VP of Manufacturing

Elena Ende

Finance Director

Steve Andress

Director of Legal

Board & advisors

Lusong Luo

Board Member

Clay Thorpe

Advisor

Teams

This company has no teams yet

Offices

HQ
0 people · 0 jobs

Amgen

305 followers

Gilead Sciences

179 followers

Regeneron

147 followers

Illumina

82 followers

Agilent Technologies

90 followers

Verily Life Sciences

48 followers

Alexion Pharmaceuticals

50 followers

GRAIL

32 followers

Cytiva

20 followers

PerkinElmer

13 followers

Editas Medicine

5 followers

��������